Reimagine Medicine | Novartis

Media Release
Nov 21, 2024
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Media Release
Nov 19, 2024
Novartis ranks first in 2024 Access to Medicine Index
Media Release
Oct 29, 2024
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Media Release
Oct 29, 2024
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
Media Release
Oct 29, 2024
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Media Release
Oct 27, 2024
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
Story
Oct 29, 2024
My Journey to Novartis: Finding my Purpose and Passion
Media Release
Oct 24, 2024
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Media Release
Oct 18, 2024
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Media Release
Sep 18, 2024
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
Media Release
Sep 17, 2024
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Media Release
Sep 16, 2024
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer